View Report
March 23, 2026
Measured Result 0.96 mg 96.00% of label claim
British Dragon
British Dragon
Latest Laboratory Result 0.96 mg March 23, 2026 · 96% of label claim View
Anastrozole 1 mg
Product Information Compound Details
Active Substance Anastrozole Nonsteroidal Aromatase Inhibitor
1 mgStrength 1 mg/tablet
Package 50 or 100 Tablets
Form Oral Tablets
Drug Class Aromatase Inhibitor
Inhibitor Type Nonsteroidal
Manufacturer British Dragon
Amount :
50 tabs
100 tabs
Shipping :
International
U.S. Domestic
Out of stock
Product Overview
Anastrozole 1 mg by British Dragon
Anastrozole 1 mg is an oral aromatase inhibitor tablet manufactured by British Dragon and dosed at 1 mg per tablet, supplied in packs of 50 or 100 tablets.
Anastrozole Oral
Anastrozole 1 mg contains anastrozole, a potent and selective third-generation non-steroidal aromatase inhibitor. It works by inhibiting the aromatase enzyme (CYP19A1), which is responsible for converting androgens into estrogens in peripheral tissues. By blocking this conversion, anastrozole reduces circulating estrogen levels, making it a clinically established treatment for hormone receptor-positive breast cancer in postmenopausal women.
In medical practice, anastrozole is FDA-approved for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, as well as first-line and second-line treatment of advanced breast cancer. The standard clinical dose is one 1 mg tablet taken once daily.
In non-medical bodybuilding and performance-enhancement contexts, anastrozole is commonly referenced as an aromatase inhibitor to manage estrogenic side effects from aromatizing anabolic steroids. Such use falls outside approved medical indications and requires careful consideration of individual response, as excessive estrogen suppression can lead to joint discomfort, adverse lipid changes, and bone density loss.
Key Properties of Anastrozole 1 mg
- Potent third-generation aromatase inhibitor with high selectivity for CYP19A1
- Reduces circulating estrogen by blocking androgen-to-estrogen conversion
- FDA-approved for breast cancer treatment in postmenopausal women
- Standard clinical dosage of 1 mg once daily
- 50 or 100 tablet pack sizes support extended research protocols
Product Profile
Anastrozole Profile
Anastrozole is a non-steroidal aromatase inhibitor that selectively binds to the aromatase enzyme, reducing estrogen synthesis in peripheral tissues.
Aromatase Inhibitor (AI)
Anastrozole works by reversibly binding to the aromatase enzyme (CYP19A1), inhibiting the conversion of androgens such as testosterone and androstenedione into estrogens including estradiol and estrone. This mechanism makes it effective at reducing circulating estrogen levels, which is the basis for its clinical use in hormone receptor-positive breast cancer.
The compound has an elimination half-life of approximately 30 to 60 hours in humans, supporting once-daily dosing. Steady-state plasma concentrations are typically reached within 7 days of daily administration.
In the clinical ATAC trial, anastrozole demonstrated efficacy in postmenopausal women with early breast cancer, with a safety profile that differed from tamoxifen. Common adverse effects included hot flashes, joint disorders, and bone mineral density decreases.
Clinical Status
FDA-Approved for Breast Cancer — Not for Research Use
Anastrozole is FDA-approved for specific breast cancer indications in postmenopausal women. Products marketed for research purposes are not approved for human use, and non-medical use falls outside approved indications.
Anastrozole 1 mg vs Other British Dragon Preparations
British Dragon offers several ancillary compounds used in non-medical bodybuilding contexts. Exemestane is a steroidal aromatase inhibitor with a different mechanism of action, while Letrobol contains letrozole, another non-steroidal AI. For post-cycle therapy, Clomiphene and Tamoxifen are commonly referenced for restoring endogenous testosterone production.
Anastrozole's distinguishing characteristic among these compounds is its potency and selectivity as a non-steroidal AI, making it a commonly referenced option for managing estrogenic side effects during aromatizing steroid cycles.
Dosage & Usage
Anastrozole 1 mg Dosage & Usage
The information below is provided for educational reference only. Anastrozole is a prescription medication; medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring. Non-medical use falls outside approved indications.
Typical Dosage Ranges
In clinical practice, the standard anastrozole dose is 1 mg taken once daily for breast cancer treatment in postmenopausal women. In non-medical bodybuilding contexts, anastrozole is commonly referenced at much lower doses for managing estrogenic side effects, typically 0.25 to 1 mg every other day or twice weekly, though such use falls outside approved indications and requires careful individual assessment.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Clinical (breast cancer) | 1 mg | Once daily |
| Non-medical AI management (conservative) | 0.25–0.5 mg | Every other day or twice weekly |
| Non-medical AI management (standard) | 0.5–1 mg | Every other day |
These non-medical ranges represent community-reported practices and are not derived from controlled clinical trials for performance enhancement. Individual response to aromatase inhibition varies, and excessive estrogen suppression carries risks including joint discomfort, adverse lipid changes, and bone density reduction.
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, anastrozole is used alongside aromatizing anabolic steroids such as testosterone or Methanabol. The goal is to mitigate estrogenic side effects including water retention, gynecomastia, and elevated blood pressure while maintaining the anabolic benefits of the cycle compounds.
Anastrozole should not be stacked with tamoxifen in clinical settings, as the combination has not shown additional benefit over tamoxifen alone. In non-medical contexts, bloodwork including estradiol, lipid profile, and liver function is commonly referenced to guide AI dosing.
Managing Side Effects
The most common adverse effects reported with anastrozole in clinical trials include hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea, and bone mineral density decreases. In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed compared to tamoxifen.
Anastrozole lowers estrogen levels, which may lead to loss of bone mineral content and increased fracture risk. Cholesterol elevations have also been reported. In non-medical contexts, excessive estrogen suppression can cause joint dryness, mood changes, and sexual dysfunction, which may be managed by adjusting dosage frequency based on individual response.
Important
Individual Response Varies
Anastrozole has approved dosing for specific medical indications. Any information about non-medical use is derived from user-reported practices and is not validated by controlled clinical research. This information does not constitute medical advice.
Laboratory Testing
Anastrozole 1 mg Lab Reports
Published laboratory reports for Anastrozole 1 mg are shown below with the test date, measured result and percentage of the product's 1 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
Safety & Information
Anastrozole Safety Information
Anastrozole is a prescription medication with known risks that require clinical oversight. It is contraindicated in premenopausal women and during pregnancy.
Important Safety Information
Anastrozole is contraindicated in women who are or may become pregnant and in premenopausal women, as it may cause fetal harm and offers no clinical benefit in this population. It is also contraindicated in patients with hypersensitivity to anastrozole or any excipients, with observed reactions including anaphylaxis, angioedema, and urticaria.
Anastrozole should not be used in combination with tamoxifen, as no additional benefit was seen over tamoxifen monotherapy, and the combination may lower anastrozole blood levels.
Important
Non-Medical Use
Non-medical use of anastrozole falls outside approved indications. Product purity does not establish that non-medical use is safe or appropriate for an individual. Estrogen suppression carries risks that may not be apparent without clinical monitoring.
Potential Adverse Effects
Common adverse reactions (incidence ≥10%) in women taking anastrozole include hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, and peripheral edema.
Anastrozole lowers estrogen levels, which may lead to decreased bone mineral density and increased fracture risk. Cholesterol elevations have also been reported. In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed compared to tamoxifen.
Serious adverse reactions occurring in less than 1 in 10,000 patients include skin reactions such as lesions, ulcers, or blisters; allergic reactions with swelling of the face, lips, tongue, and/or throat; and changes in liver function tests.
Conditions Requiring Medical Evaluation
Anastrozole is not appropriate for everyone. Contraindications include pregnancy, premenopausal status, and hypersensitivity to the drug. Caution is advised in patients with pre-existing ischemic heart disease, osteoporosis, or high cholesterol.
Patients should inform their healthcare provider of any heart problems, bone thinning or weakness, high cholesterol, or other medical conditions before taking anastrozole.
Monitoring During Therapy
Medically supervised anastrozole therapy may involve monitoring of bone mineral density, serum cholesterol, and cardiovascular status. In clinical settings, the ATAC trial demonstrated the need for bone density monitoring in patients receiving anastrozole.
Product Care
Storage & Handling
Store tablets in a cool, dry place in the original packaging. Keep out of reach of children. Inspect tablets before use and do not use if they appear damaged or compromised.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
Anastrozole 1 mg is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official British Dragon distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Anastrozole 1 mg product, use the security code on the packaging and cross-check it on the British Dragon official site. Official British Dragon presentation and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
Anastrozole 1 mg Storage
Proper storage conditions help preserve tablet stability and overall product integrity throughout shelf life.
Recommended Conditions
Store at controlled room temperature (15–25°C) in a cool, dry place, away from direct light and moisture. Keep tablets in their original blister packaging or container until use to protect from humidity.
Inspect tablets before use and do not use if they appear discolored, cracked, or otherwise compromised. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do inspect before each use
- Don't expose to direct sunlight or moisture
- Don't store in bathroom or humid areas
- Don't use if tablets appear abnormal
Frequently Asked Questions
Anastrozole 1 mg FAQ
Answers to common questions about Anastrozole 1 mg, the Anastrozole compound, and its applications.
What is Anastrozole 1 mg used for?
Anastrozole 1 mg contains the aromatase inhibitor anastrozole. In clinical medicine, it is approved for treatment of hormone receptor-positive breast cancer in postmenopausal women. In non-medical bodybuilding contexts, it is commonly referenced for managing estrogenic side effects from aromatizing anabolic steroids, though such use falls outside approved indications.
How often should Anastrozole 1 mg be taken?
The standard clinical dose is one 1 mg tablet taken once daily for breast cancer treatment. In non-medical contexts, anastrozole is commonly referenced at lower doses of 0.25–1 mg every other day or twice weekly. These non-medical practices are not derived from controlled clinical trials for performance enhancement.
Does Anastrozole 1 mg require PCT?
Anastrozole is an aromatase inhibitor, not an anabolic steroid, and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to anastrozole in the context of hormonal recovery. In non-medical settings, PCT protocols typically involve Clomiphene or Tamoxifen rather than anastrozole.
What does Anastrozole do?
Anastrozole inhibits the aromatase enzyme (CYP19A1), which converts androgens into estrogens in peripheral tissues. By blocking this conversion, it reduces circulating estrogen levels. This mechanism underlies its clinical use in hormone receptor-positive breast cancer and its non-medical use for managing estrogenic side effects.
How long does Anastrozole take to work?
Anastrozole has an elimination half-life of approximately 30 to 60 hours, and steady-state plasma concentrations are typically reached within 7 days of daily administration. Estrogen suppression begins rapidly after the first dose, though clinical effects on hormone levels may take several days to fully manifest.
Is Anastrozole the best aromatase inhibitor?
There is no universally established "best" aromatase inhibitor, and each has distinct characteristics. Anastrozole is a non-steroidal AI with high selectivity for the aromatase enzyme. Other AIs such as exemestane (steroidal) and letrozole (non-steroidal) have different mechanisms and potency profiles.
What is the difference between Anastrozole and Exemestane?
Anastrozole and Exemestane are both aromatase inhibitors but differ in type. Anastrozole is a non-steroidal, reversible inhibitor, while exemestane is a steroidal, irreversible (suicide) inhibitor. They have different potency profiles and side effect characteristics.
What is the difference between Anastrozole and Letrozole?
Anastrozole and Letrobol (letrozole) are both non-steroidal aromatase inhibitors. Letrozole is generally considered more potent at suppressing estrogen, while anastrozole has a broader clinical history in breast cancer treatment and a potentially more favorable side effect profile at standard doses.
Is 1 mg of Anastrozole a lot?
Anastrozole 1 mg is the standard clinical dose for breast cancer treatment in postmenopausal women. In non-medical bodybuilding contexts, 1 mg is often considered a high dose for estrogen management, and lower doses or less frequent administration are commonly referenced to avoid excessive estrogen suppression.
What strength is Anastrozole 1 mg?
Anastrozole 1 mg is labeled at 1 mg of anastrozole per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.
Is Anastrozole 1 mg lab tested?
Yes. A published laboratory report dated March 23, 2026 measured Anastrozole 1 mg at 0.96 mg, equivalent to 96.00% of its 1 mg label claim. The complete report can be viewed in the Lab Reports tab.
Related Offers
Lab Tested
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Testosterone Cypionate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable
Estimated Half-Life Approximately 8 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer British Dragon
Lab Tested
British Dragon Pharmaceuticals
Product Information Compound Details
Active Substance Testosterone Enanthate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable
Estimated Half-Life Approximately 7–9 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information Compound Details
Active Formula Testosterone Blend
350 mg/mLTestosterone Propionate 42 mg
Testosterone Isocaproate 84 mg
Testosterone Phenylpropionate 84 mg
Testosterone Decanoate 140 mg
Total Strength 350 mg/mL
Package 10 mL Vial 3,500 mg total labeled content
Form Oil-Based Injectable
Formula 4-Ester Testosterone Blend
Drug Class Androgen & Anabolic Steroid
Manufacturer British Dragon
British Dragon Pharmaceuticals
Product Information
Compound Details
Active Substance
Clomiphene Citrate
Selective Estrogen Receptor Modulator (SERM)
50 mg
Strength
50 mg/tablet
Package
50 or 100 Tablets
Form
Oral Tablets
Drug Class
SERM
Selective Estrogen Receptor Modulator
Estimated Half-Life
Approximately 5–7 Days
Manufacturer
British Dragon